My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Clotting Factor VIII Biosimilar

Clotting Factor VIII Biosimilar

Advate Biosimilar, Kogenate Biosimilar, Moroctocog Alfa, Recombinant Antihemophilic Factor VIII, Recombinant Clotting factor VIII

Catalog No. Product Name Size List Price (US$) Quantity
Description

Advate / Kogenate is used to replace clotting factor VIII to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Haemophilia A, about 80% of haemophilia cases and present in about 1 in 5,000–10,000 male births, is a recessive X-linked genetic disorder and caused by deficiency in the functional clotting Factor VIII. Without the functional clotting Factor VIII, bodies of patients with Haemophilia A lose the control of normal blood clotting or coagulation, critical to stop bleeding when a blood vessel is broken.

C018: Advate / Kogenate Biosimilar Stable Cell Line

The yield of Advate / Kogenate Biosimilar from the CHO stable cell line was above 60 IU/ml in a 50 liter manufacturing.

The Advate / Kogenate Biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following clotting or coagulation-related biosimilar stable cell lines:
ReFacto Biosimilar Stable Cell Line (truncated Factor VIII)
NovoSeven Biosimilar Stable Cell Line (Factor VIIa)
BeneFIX Biosimilar Stable Cell Line (Factor IX)

Related Links

See our Privacy Policy